News

Mint PI-RADS v2 report as standard for communication with urologists

Since the beginning of 2017, all PI-RADS v2 reads are exclusively performed with mint Lesion by PD Dr. Matthias Röthke, Chief Medical Officer at Conradia in Hamburg (see exemplary Mint report here). In this interview he outlines the challenges of prostate cancer assessment and how Mint…

Pancreas staging in clinical routine at University Hospital Innsbruck

The University Hospital in Innsbruck, Austria, has been using mint Lesion since mid-2015 with the initial focus on clinical trials in order to guarantee the conformity with the guidelines defined in the trial protocol, especially with regards to the requested criteria like RECIST 1.1. With…

Assessment time halved: Importance of a good tumor response assessment tool in clinical site reads

The Clinical Research Imaging Core (CRIC) of the University of Wisconsin Carbone Cancer Center (UWCCC) recently published a poster at the AACI CRI conference titled “Shared Investment to Build a Strong, Streamlined, and Accessible RECIST Foundation in Clinical Research”. On this poster, core manager Mr….

Mint’s US growth continues – Ms. Andjela Azabagic joins Mint Medical

Mint Medical is further boosting the US business and announces the addition of Andjela Azabagic, as Vice President Business Development, to the US team. Andjela is an experienced business and marketing professional with background in growing domestic and international business and product strategy in the...

Research with Mint: Pilot study shows discriminatory power of MRI-based 3D texture analysis for bone lesions

Distinguishing between enchondroma, a benign tumor, and low-grade chondrosarcoma, which is a low-aggressivity malignancy, is a frequent challenge, as the lesions are both histologically and radiographically very similar. Given the fact that enchondroma only requires regular follow-up but chondrosarcoma needs surgical resection, differentiating between them...

Study – free text reporting vs. mint Lesion in clinical routine

Free text reporting in the tumor response assessment of radiologic imaging data is common in clinical routine, whereas in clinical trials standardized computer-aided response assessment is already used rather frequently. Juliane Goebel, Julia Hoischen, Carolin Gramsch, Haemi P. Schemuth, Andreas‑Claudius Hoffmann, Lale Umutlu and Kai...

6 years of Mint at University Hospital Basel – Interview with PD Dr. Tobias Heye

Since end of 2011, mint Lesion has been in use at the University Hospital in Basel, Switzerland, - initially merely as a tool for clinical trials, but now also as the standard instrument for the entire oncologic radiology in clinical routine. We talked with PD Dr....

New iRECIST whitepaper published

We are happy to present our newly published whitepaper on iRECIST and its application. This is available here on our homepage as well as on www.irecist.com. Mint Medical had already implemented the iRECIST criteria in May 2017 for its new version of the mint LesionTM...

4 Questions – 4 Answers // Imaging in Clinical Trials

Mint Medical, Inc. Vice President of Clinical Trials, Kelie Luby Discusses Advances in Imaging Analysis in Clinical Trials and What’s Next for Mint Medical     What advancements in imaging analysis in clinical trials do you think have been most impactful in the past several...

Joint partnership between Mint Medical and Siemens Healthineers syngo.via

Siemens Healthineers and Mint Medical joined forces to accelerate imaging and result reporting software availability in hospitals when and where it is needed. This collaboration, announced at the 2017 Radiological Society of North America (RSNA) Annual Meeting on November 27th 2017, will enable users to...